Literature DB >> 2244589

Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors.

P Vielh1, S Chevillard, V Mosseri, B Donatini, H Magdelenat.   

Abstract

In a prospective study of 148 consecutive breast adenocarcinomas, proliferative indices of the same surgical tumor sample were performed by immunohistologic staining (Ki67 index) with the use of the Ki67 monoclonal antibody, which binds to a nuclear antigen only expressed in cycling cells, and by flow cytometry-derived S-phase fraction (SPF). Measurable Ki67 and SPF indices were obtained in 142 cases and 99 cases, respectively, and in 96 cases by both methods. In aneuploid tumors, a significant but low (P less than 0.05, r = 0.3) relationship was observed between Ki67 index and SPF. When compared with clinical, pathologic, and biochemical parameters these two proliferative indices were shown to be associated with nuclear grading and mitotic index. Additionally, correlations were observed between Ki67 index and node involvement (P less than 0.02) and between SPF and estrogen receptors (P = 0.002). These results show that (1) proliferative indices are obtained in 96% of surgical samples with Ki67 versus 67% with SPF and that (2) Ki67 index and SPF may provide complementary data with respect to prognosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2244589     DOI: 10.1093/ajcp/94.6.681

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  21 in total

1.  Multicentric Breast Carcinoma: Evaluation of Clinicopathological and Immunohistochemical Characteristics.

Authors: 
Journal:  Breast Cancer       Date:  1996-12-20       Impact factor: 4.239

2.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

3.  Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma?

Authors:  G Valente; R Orecchia; S Gandolfo; M Arnaudo; R Ragona; S Kerim; G Palestro
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

4.  Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma.

Authors:  A E Pinto; S André; T Pereira; S Nóbrega; J Soares
Journal:  J Clin Pathol       Date:  2001-07       Impact factor: 3.411

5.  Comparison between different cell kinetic variables in human breast cancer.

Authors:  F Barzanti; M Dal Susino; A Volpi; D Amadori; A Riccobon; E Scarpi; L Medri; L Bernardi; S Naldi; M Aldi; M Gaudio; W Zoli
Journal:  Cell Prolif       Date:  2000-04       Impact factor: 6.831

6.  Comparison of PCNA/cyclin immunohistochemistry with flow cytometric S-phase fraction in breast cancer.

Authors:  D W Visscher; S Wykes; J Kubus; J D Crissman
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

7.  PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables.

Authors:  E Leonardi; S Girlando; G Serio; F A Mauri; G Perrone; S Scampini; P Dalla Palma; M Barbareschi
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

8.  Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases.

Authors:  A Russo; M Migliavacca; V Bazan; N Maturi; V Morello; G Dardanoni; G Modica; P Bazan; I Albanese; M La Farina; R M Tomasino
Journal:  Cell Prolif       Date:  1998 Jun-Aug       Impact factor: 6.831

9.  DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients.

Authors:  C R Wenger; S Beardslee; M A Owens; G Pounds; T Oldaker; P Vendely; M R Pandian; D Harrington; G M Clark; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

10.  Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.

Authors:  Thomas E Rohan; Xiaonan Xue; Hung-Mo Lin; Timothy M D'Alfonso; Paula S Ginter; Maja H Oktay; Brian D Robinson; Mindy Ginsberg; Frank B Gertler; Andrew G Glass; Joseph A Sparano; John S Condeelis; Joan G Jones
Journal:  J Natl Cancer Inst       Date:  2014-06-03       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.